John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cisco
CSCO
|
+$226M |
| 2 |
JPMorgan Chase
JPM
|
+$212M |
| 3 |
TSMC
TSM
|
+$204M |
| 4 |
Occidental Petroleum
OXY
|
+$194M |
| 5 |
Apple
AAPL
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$271M |
| 2 |
Microsoft
MSFT
|
+$267M |
| 3 |
Canadian Pacific Kansas City
CP
|
+$255M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$226M |
| 5 |
Coca-Cola
KO
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.48% |
| 2 | Healthcare | 15.21% |
| 3 | Industrials | 10.23% |
| 4 | Consumer Discretionary | 10.15% |
| 5 | Financials | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Atossa Therapeutics
ATOS
$26.7M
| $698K | ﹤0.01% |
37,233
-120,847
| -76% | -$2.46M |
|
1852
Precision BioSciences
DTIL
$236M
| $698K | ﹤0.01% |
+7,556
| New | +$1.03M |
|
|
MRUS
1853
DELISTED
Merus
MRUS
| $695K | ﹤0.01% |
26,300
-84,583
| -76% | -$2.27M |
|
|
NOVA
1854
DELISTED
Sunnova Energy
NOVA
| $691K | ﹤0.01% |
+29,961
| New | +$641K |
|
1855
Shore Bancshares
SHBI
$771M
| $689K | ﹤0.01% |
33,652
-3,227
| -9% | -$66.2K |
|
|
AAIC
1856
DELISTED
Arlington Asset Investment Corp.
AAIC
| $689K | ﹤0.01% |
198,466
-93,728
| -32% | -$324K |
|
1857
Spero Therapeutics
SPRO
$71.6M
| $686K | ﹤0.01% |
+78,908
| New | +$808K |
|
1858
Rafael Holdings
RFL
$116M
| $681K | ﹤0.01% |
275,306
-49,684
| -15% | -$170K |
|
1859
Royal Gold
RGLD
$22.7B
| $680K | ﹤0.01% |
4,810
-53,245
| -92% | -$6.22M |
|
1860
Vontier
VNT
$4.51B
| $679K | ﹤0.01% |
+26,754
| New | +$707K |
|
1861
TPG
TPG
$8.82B
| $678K | ﹤0.01% |
+22,500
| New | +$696K |
|
1862
FVCBankcorp
FVCB
$332M
| $677K | ﹤0.01% |
+40,803
| New | +$675K |
|
|
MOFG
1863
DELISTED
MidWestOne Financial Group
MOFG
| $676K | ﹤0.01% |
20,426
-1,547
| -7% | -$49.5K |
|
1864
Hilton Worldwide
HLT
$74.1B
| $675K | ﹤0.01% |
4,446
-20,578
| -82% | -$3.03M |
|
1865
Unifirst Corp
UNF
$5.21B
| $675K | ﹤0.01% |
3,665
-22,000
| -86% | -$4.07M |
|
1866
ProQR Therapeutics
PRQR
$336M
| $674K | ﹤0.01% |
+744,377
| New | +$2.49M |
|
1867
MACOM Technology Solutions
MTSI
$20.3B
| $673K | ﹤0.01% |
+11,234
| New | +$702K |
|
|
BORR
1868
Borr Drilling
BORR
$1.38B
| $668K | ﹤0.01% |
+199,460
| New | +$509K |
|
|
CKPT
1869
DELISTED
Checkpoint Therapeutics
CKPT
| $667K | ﹤0.01% |
+37,705
| New | +$810K |
|
|
SP
1870
DELISTED
SP Plus Corporation
SP
| $665K | ﹤0.01% |
+21,219
| New | +$614K |
|
1871
BeyondSpring
BYSI
$29.6M
| $660K | ﹤0.01% |
299,990
-170,914
| -36% | -$496K |
|
1872
Axogen
AXGN
$2.68B
| $658K | ﹤0.01% |
82,844
-38,334
| -32% | -$331K |
|
1873
Insmed
INSM
$27.1B
| $653K | ﹤0.01% |
27,800
+300
| +1% | +$6.97K |
|
|
CMBT
1874
CMB.TECH NV
CMBT
$5.27B
| $653K | ﹤0.01% |
61,734
+26,134
| +73% | +$259K |
|
1875
Liberty Latin America Class C
LILAK
$1.67B
| $651K | ﹤0.01% |
+74,713
| New | +$710K |
|
Similar funds
John Overdeck's Q1 2022 Portfolio in Review
As of Q1 2022, John Overdeck held 4,846 positions worth $33.9B, down 28% from $46.8B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
John Overdeck withdrew a net $11.3B in Q1 2022, closing 2,304 positions and reducing 976 holdings. Its most notable exit was Pfizer, an estimated $271M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, John Overdeck opened a new position in Cisco worth $223M.
- John Overdeck's largest Q1 2022 buy was Cisco: 4,001,362 shares worth $223M.
- John Overdeck added most to JPMorgan Chase in Q1 2022, an estimated $212M increase.
- John Overdeck's biggest Q1 2022 reduction was Coca-Cola, cutting an estimated $225M.
- John Overdeck fully exited Pfizer in Q1 2022, selling an estimated $271M.
- John Overdeck's ten largest holdings make up 7.2% of its $33.9B portfolio in Q1 2022.
- John Overdeck opened 656 new positions and closed 2,304 in Q1 2022.
- John Overdeck's portfolio value fell 28% quarter-over-quarter to $33.9B.
Based on Two Sigma Investments's 13F filing for Q1 2022, filed 16 May 2022.